Saturday 17 October 2026
Export ATNM’s income statement to Excel — free account
Actinium Pharmaceuticals, Inc.
ATNM Healthcare Biotechnology
Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023. In the quarter to June 2026, revenue grew 77,677.8%, EPS grew 504.6% and free cash flow fell 4.91%, each against the same quarter a year earlier.
1.13
0.07
+6.60%
Follow ATNM
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | — | — | 2.72 |
P/S ratio |
277.30 | — | — | 0.88 | |
P/FCF ratio |
0.00 | — | — | 0.00 | |
P/Operating CF |
(7.89) | — | — | (5.94) | |
P/B ratio |
3.62 | — | — | 1.02 | |
Price to Tangible BV |
3.62 | — | — | 1.02 | |
EV/Sales |
(19.31) | — | — | (0.16) | |
EV/EBITDA |
0.10 | — | — | 0.00 | |
EV/Operating CF |
0.14 | — | — | 0.25 | |
EV/FCF |
0.14 | — | — | 0.25 | |
Quick Ratio |
7.81 | 6.02 | 5.73 | 3.94 | |
Current Ratio |
7.96 | 6.20 | 5.89 | 4.08 | |
Net Debt/EBITDA |
9.73 | 7.73 | 7.41 | (1.31) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.68 | |
Operating CF/Net income |
1.23 | 0.89 | 1.06 | (0.19) | |
Capex/Depreciation |
0.00 | (0.50) | (0.01) | (1.98) | |
Research and Development Expense of Revenue |
4,720.00% | 0.00% | 0.00% | 15.36% | |
Selling, General and Administrative Expense of Revenue |
1,704.44% | 0.00% | 0.00% | 5.88% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
121.11% | 0.00% | 0.00% | 0.34% | |
Graham Net Nets |
0.24 | — | — | 0.91 | |
Graham Number |
0.00 | — | — | 2.80 | |
Earnings Yield |
(68.75%) | — | — | 36.73% | |
Free Cash Flow Yield |
(50.19%) | — | — | (75.55%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 1.11 | |
Operating CF per Share |
(0.20) | (0.17) | (0.19) | (0.16) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.02) | |
Free Cash Flow per Share |
(0.20) | (0.17) | (0.19) | (0.18) | |
Cash per Share |
1.71 | 1.54 | 1.35 | 1.16 | |
Shareholders Equity per Share |
0.44 | 0.25 | 0.07 | 0.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.44 | 0.25 | 0.07 | 0.97 | |
Free Cash Flow |
(6.32) | (5.39) | (5.87) | (5.66) | |
Working Capital |
47.53 | 41.41 | 35.91 | 28.48 | |
Capital Expenditures |
— | (0.10) | 0.00 | (0.48) | |
Net Current Asset Value |
12.00 | 5.44 | 0.13 | 27.89 | |
EV/EBIT |
0.09 | — | — | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | — | — | 3.22 | |
| Other line items | |||||
Average Payables |
6.71 | 7.41 | 6.57 | 8.11 | |
Average Assets |
69.13 | 64.34 | 57.04 | 51.59 | |
Average Common Equity |
26.00 | 20.30 | 14.00 | 24.66 |
Columns are period end dates